

AC Immune raises CHF 20 million and initiates world's first anti-pTau vaccine trial for Alzheimer's disease

- **CHF 20 million round D secured from existing investors**
- **World's first Alzheimer's vaccine trial against phospho-Tau hallmark**

Lausanne, Switzerland, 9 January, 2014 – AC Immune SA announced today it has successfully completed its round D financing by raising CHF 20 million from current private investors. The company also announced it has started the world's first trial of a vaccine against the phospho-Tau target for Alzheimer's disease.

Prof. Andrea Pfeifer, CEO of AC Immune said: "We are very pleased to have secured these funds which enable us to continue building our extensive pipeline focused on Alzheimer's and related diseases. We are breaking new ground with the world's first-ever vaccine targeting phospho-Tau which is now recognized as a key hallmark of Alzheimer's disease." She continued: "The recent G8 Summit on Dementia in London highlighted the commitment by policy makers and experts of significant new financial and healthcare resources in quest of a cure for these terrible diseases. AC Immune is proud to be part of this global effort."

"I am delighted that our current investors have demonstrated their continued confidence in the company's science, clinical programs and management team. We look forward to further success in meeting the challenges of this important disease area," commented **Martin Velasco, Chairman of the Board**.

CHF 20 million Financing Round D

The successful financing of CHF 20 million was fully subscribed by existing private investors who have now committed a total of CHF 84 million in four rounds since AC Immune was founded in 2003. The company will call on the latest funds in two tranches according to its financial requirements.

The new funds, along with existing cash resources, will enable AC Immune to further advance its clinical and pre-clinical drug pipeline. These resources will mainly support the newly initiated groundbreaking clinical trial of the anti-pTau vaccine ACI-35.

About anti-pTau vaccine ACI-35 and the clinical trial

ACI-35 is an active vaccine, discovered by AC Immune, stimulating the patient's immune system to produce conformation-specific antibodies against phosphorylated Tau protein. The phospho-Tau protein forms twisted fibers inside neuronal cells and builds tangles that are considered to be one of the two hallmarks of Alzheimer's disease, besides Abeta-plaques. During pre-clinical development, ACI-35 showed reduction of phospho-Tau aggregates and total pathological Tau and improvement of clinical parameters. The vaccine ACI-35 is also characterized by very specific antibody response against

pathological Tau and its T-cell independent immune response, an important feature of AC Immune's SupraAntigen technology platform, supporting the excellent safety profile.

The clinical trial is a Phase I, randomized, double blind, placebo controlled clinical study with the primary objective of evaluating the safety, tolerability and immunogenicity of ACI-35. Secondary objectives will assess relevant biomarkers and functional and clinical parameters. Two groups of patients with mild or moderate Alzheimer's disease will receive a different dose of ACI-35. Patient safety in the study has been secured by careful planning and extensive preclinical tests.

Crenezumab progress

AC Immune benefits from two existing major collaborations with Genentech, the most advanced of which is a Phase II trial of crenezumab in Alzheimer's disease which is due to report data in 2014. Crenezumab is also being tested in the groundbreaking Alzheimer's Prevention Initiative (API) trial in Colombia, which marked a milestone with the first participants receiving doses of crenezumab in December 2013.

About AC Immune

AC Immune SA is a Swiss-based biopharmaceutical company and a leader in Alzheimer's disease drug development. AC Immune develops innovative therapeutics with "best in class" potential against Alzheimer's disease and other conformational diseases along three axes: vaccines, antibodies and small molecules. The anti-Abeta antibody (crenezumab) for passive immunization is partnered with Genentech and is in Phase II development; it has been selected for the first groundbreaking Alzheimer's prevention trial. The company pursues the clinical development of the vaccines ACI-24 and ACI-35. These three clinical programs are focused on Alzheimer's disease, and are backed by a rich portfolio of preclinical compounds. A preclinical stage anti-Tau antibody is also partnered with Genentech. The therapeutic molecules are leveraged for Alzheimer's disease diagnostic and other central nervous system and non-CNS diseases, such as Glaucoma and Down syndrome. Since its foundation in 2003, AC Immune has raised CHF 84 million from private investors.

For further information, please contact:

Prof. Andrea Pfeifer
Chief Executive Officer
Phone: +41-21-693 91 21
E-mail: andrea.pfeifer@acimmune.com
www.acimmune.com

Eva Schier
Corporate Communications Manager
Phone: +41-21-693 91 34
E-mail: eva.schier@acimmune.com
www.acimmune.com

Nick Miles
Senior Consultant
Cabinet Privé de Conseils s.a.
Phone : +41 22 321 45 40
Mobile : +41 79 678 76 26
E-mail : miles@cpc-pr.com

In the US
Ted Agne
The Communications Strategy Group Inc.
Phone: +1 781 631 3117
E-mail: edagne@comstratgroup.com